QIAGEN Announces First-ever Regulatory Registration of a Lung Cancer Companion Diagnostic Based on Liquid Biopsies in Collaboration With AstraZeneca

By: via Benzinga
QIAGEN (NASDAQ: QGEN) announced today the CE-IVD marking of its novel liquid biopsy-based companion diagnostic that analyzes circulating ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.